Malaria falciparum

This study tests a new malaria vaccine called SUM-101 in 69 healthy children and infants aged 5 months to 5 years in Burkina Faso. The goal is to see if the vaccine is safe and triggers a strong immune response. Participants receive three doses, and some infants also receive a ra…

This trial tests an experimental malaria vaccine called RH5.2-VLP, given with an adjuvant (Matrix-M) to boost the immune response. Healthy adults aged 18–45 receive three doses, and some volunteers are later exposed to malaria parasites in a controlled setting to see if the vacci…

This study tested a new malaria vaccine made from genetically weakened parasites that stop growing in the liver and cannot cause blood-stage infection. The goal was to see if it is safe and triggers a strong immune response. The trial involved 75 healthy adults and children in Bu…

This early-stage trial tested a new malaria vaccine called AMA1-DiCo in 66 healthy adults—some in Europe never exposed to malaria, and some in Africa who were. The vaccine was given with one of two adjuvants (GLA-SE or Alhydrogel) to boost immune response. The main goal was to ch…

This study looked at whether finding and treating low-density malaria infections (infections with very few parasites) in children can improve their health and well-being over time. 600 children in Tanzania, aged 6 months to 10 years, took part. The goal was to see if this approac…

This study tested a monoclonal antibody called TB31F in 167 adults and children in Mali who are regularly exposed to malaria. The goal was to see if the antibody is safe and can reduce the spread of the malaria parasite from humans to mosquitoes. Participants received either the …

This study tests whether giving school children preventive malaria medicine can reduce infections not only in them but also in younger siblings at home. About 1,000 students in rural Malawi will receive either one of two drug combinations or no preventive treatment. Researchers w…

This early-stage trial is testing a new drug called GSK4024484 in 156 healthy adults to see if it is safe and how the body handles it. Researchers will also check if food affects the drug. The goal is to gather safety information before testing it in people with malaria.

This study tests a single injection of a new long-acting malaria drug called MMV371 in 32 healthy adults. The main goal is to check if it is safe and how the body processes it. Participants receive either the drug or a placebo and are monitored for about 12 weeks for side effects…

This completed study in western Kenya looked at how well different malaria drugs work and whether the parasites are becoming resistant. Researchers tested four artemisinin-based combination therapies across 28 health facilities over 28 months, involving 316 people with uncomplica…

This study tested a new experimental drug called MMV367 in 12 healthy adults. Participants were intentionally infected with a controlled, low-level malaria infection to see how well the drug works and how safe it is. The goal was to measure how the body processes the drug and how…